Because our results and previous studies demonstrate that AR expression has prognostic value, it is recommended that AR status should be evaluated for patients with HER2-enriched breast cancer upon initial diagnosis to obtain comprehensive information. The gene discussed is ERBB2; the disease is breast carcinoma.